Sphere Fluidics
 | This article uses too much jargon, which needs explaining or simplifying. (January 2024) |
 | This article needs to be updated. (January 2024) |
| Company type | Private |
|---|---|
| Industry | Research and Development |
| Founded | February 24, 2010 |
| Founder | Dr. Frank. F. Craig, Professor Wilhelm Huck, Professor Chris Abell and Dr. Maher Khaled |
| Headquarters | Cambridge , United Kingdom |
Area served | Worldwide |
| Services | biochemical and anti-micobial screening, synthetic biology, genome editing of single cells. |
| Website | www |
Sphere Fluidics is an Cambridge-based Life Sciences Research and Development company specializing in developing novel tools for biopharmaceutical discovery and development, cell therapy engineering, analysis and isolation.[1] Sphere Fluidics has been named one of the UK's top 50 disruptive SMEs by Real Business in 2015.[2]
History[change | change source]
Sphere Fluidics Limited was originally established in 2010, by two chemistry professors of Cambridge University, Professor Chris Abell[3] and Professor Wilhelm Huck along with Dr. Frank F. Craig, an entrepreneur, and Dr. Maher Khaled, a Cambridge University Enterprise.[4]
In 2013, Sphere Fluidics spun out of Cambridge University to a new research facility in Babraham Research Campus. In 2013, Sphere Fluidics won an award for academic spin-outs at the ACES awards.[5][6]
Overview[change | change source]
Sphere Fluidics operates in various markets including biopharmaceutical discovery and development, anti-microbial screening, synthetic biology and genome editing of single cells. [1]
In January 2017, Sphere Fluidics launched an e-commerce platform which had microfluidic products, research instrument accessories, and microfluidic biochips, in its product line.[7][8]
In July 2017, Sphere Fluidics won “Best Investment in Life Sciences” Award, in the event held by the UK Business Angels Association.[9][10]
Funding[change | change source]
Sphere Fluidics had raised £11 million as of 2017, from investors namely, 24 Haymarket,[11] Amadeus Capital Partners, Greenwood Way Capital, University of Cambridge Enterprise, University of Cambridge, Parkwalk Advisors, Providence Investment Company, London Business Angels,[12] Envestors, Angels5K, Cambridge Angels, Q-Ventures and a Japanese corporate investor.[13][14]
Cyto-Mine Technology[change | change source]
Cyto-Mine Technology is one of the patented products of Sphere Fluidics.[15]
Cyto-Mine technology is the integrated device that is able to automatically perform single cell analysis, sorting, imaging and dispensing into individual wells of microtitre plates in a single compact system.[13] Based on the research made by Professors Chris Abell and Wilhelm Huck, this biochip system can automatically process millions to billions of miniaturised tests in tiny picodroplets.[16]
According to the scientists at Sphere Fluidics, Cyto-Mine can perform millions of single-cell assays daily, offering up to a 100-fold improvement over conventional techniques, at lower capital and operational cost. [13]
References[change | change source]
- ↑ 1.0 1.1 "Sphere Fluidics Raises $7 Million for Development Of Cyto-Mine Single Cell Analysis System - SynBioBeta". synbiobeta.com. Archived from the original on 2017-09-18. Retrieved 2017-09-13.
- ↑ site., Who made this. "Sphere Fluidics named one of Britain's most disruptive businesses - Cambridge Enterprise". Cambridge Enterprise. Retrieved 2017-09-13.
- ↑ "From farm to fame, Cambridge's 'cereal' life science entrepreneur | Business Weekly | Technology News | Business news | Cambridge and the East of England". www.businessweekly.co.uk. Archived from the original on 2017-09-18. Retrieved 2017-09-13.
- ↑ "Sphere Fluidics: Single cell analysis has never looked so disruptive - Real Business". Real Business. 2015-03-04. Retrieved 2017-09-13.
- ↑ site., Who made this. "Sphere Fluidics wins award for academic spin-outs - Cambridge Enterprise". Cambridge Enterprise. Retrieved 2017-09-13.
- ↑ "Sphere Fluidics Wins Award for Academic Spin-Outs Labmate Online". www.labmate-online.com. Retrieved 2017-09-13.
- ↑ Dealmakers, BioPharma (2017-01-24). "Sphere Fluidics Launches E-commerce Site Allowing Researchers Rapid Access to Specialist Microfluidic Products". BioPharma Dealmakers. Retrieved 2017-09-13.[permanent dead link]
- ↑ "Sphere Fluidics Launches E-commerce Site Allowing Researchers Rapid Access to Specialist Microfluidic Products - Scientific Technology News". Scientific Technology News. 2017-01-24. Retrieved 2017-09-13.
- ↑ "Angels on the side of Cambridge trio | Business Weekly | Technology News | Business news | Cambridge and the East of England". www.businessweekly.co.uk. Archived from the original on 2017-07-17. Retrieved 2017-09-13.
- ↑ "UK Angel Investment Awards: Powervault Wins Best Angel Crowdfunding Investment, Digital Fineprint Wins Best Fintech Investment | Crowdfund Insider". Crowdfund Insider. 2017-07-08. Retrieved 2017-09-13.
- ↑ "Investment flows towards Sphere Fluidics · Articles · Global University Venturing". www.globaluniversityventuring.com. Archived from the original on 2017-09-18. Retrieved 2017-09-13.
- ↑ "London Business Angels investment helps Sphere Fluidics close £1.6m early stage funding round". Business Matters. 2013-03-10. Retrieved 2017-09-13.
- ↑ 13.0 13.1 13.2 "Sphere Fluidics: biotherapeutics device attracts $7m investment - GOV.UK". www.gov.uk. Retrieved 2017-09-13.
- ↑ "Sphere Fluidics successfully closes a £1.6 million Series A investment round". Cambridge Network. Archived from the original on 2017-09-18. Retrieved 2017-09-13.
- ↑ "Sphere Fluidics: Ramping up Growth to Find the "One in a Billion"! | Evaluate". www.evaluategroup.com. Retrieved 2017-09-13.[permanent dead link]
- ↑ site., Who made this. "Sphere Fluidics wins $7 million for development of single cell analysis system - Cambridge Enterprise". Cambridge Enterprise. Retrieved 2017-09-13.